Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 9, 2017 in Breast cancer | 0 comments

In a nutshell

This study aimed to investigate the association between ipsilateral breast tumor recurrence (IBTR) and the timing of radiotherapy. This study found that a delay of more than 12 weeks in starting radiotherapy was associated with a higher risk of IBTR in women undergoing BCS for ductal carcinoma in situ.

Some background

Breast conserving surgery (BCS) followed by radiotherapy is a treatment option for ductal carcinoma in situ breast cancer. This combination has been shown to decrease the 10-year risk of IBTR of 15%. It is unclear if the timing of radiotherapy affects cancer recurrence rates.

Methods & findings

This study included information on 1323 women who had BCS followed by radiotherapy. Patients were followed for an average of 6.6 years, with 311 patients followed for more than 10 years. 61% of patients had radiotherapy less than 8 weeks after BCS (group 1). 29% of patients had radiotherapy between 8 and 12 weeks after BCS (group 2). 10% of patients underwent radiotherapy 12 weeks after BCS (group 3).

There were 126 instances of IBTR.

The 10-year recurrence rate was 13% for group 1, 7.6% for group 2, and 23% for group 3. Patients in group 3 had a 92% increased risk of IBTR compared to group 1. 

Menopause and endocrine therapy had a protective effect against IBTR.

The bottom line

This study concluded that a delay of more than 12 weeks in starting radiotherapy was associated with a higher risk of IBTR in women undergoing BCS for ductal carcinoma in situ.

The fine print

This study is retrospective and so cannot determine the cause of associations, further studies may be necessary to get a clearer picture.

Published By :

Cancer

Date :

Sep 28, 2017

Original Title :

Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.

click here to get personalized updates